Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Blimey , if we can keep a decent rise today those 2 nutters on the other site Wolfie and Peace will probably self combust.
By my estimation RF have around 350k shares left.
Do with the Riverfort brakes off we should climb steadily up until news.
I did put a few weeks back that somebody here who had a 61 p average should be on profit by the end of this month.
Looking ok at the moment and price is heading closer to where it should be.
Close on a 40 million market cap at the moment.
Peanuts in reality for what we have.
Regards
Yes, the excitement is gaining momentum with P1a data due from Oz very soon. Those that understand this share will know that SAR gained x46 approx from .2p to 9p+ in pre consolidation money (or from 10p to 450p+ in post consolidation money). i.e. A 4,600% gain. Excellent returns were made by many on here during the x 4,600% rise and surprise surprise the current share price is back where it was pre the mega rise. Just in time for data to be released.
For newbies, here's some background:
1. Sareum is a company that has all its global patent ducks in a row.
2. Sareum has already produced data showing that its lead candidate SDC-1801 is superior to Dexamethasone in a trial.
3. Sareum has shown that its science in combo with Astra Zeneca's WEE1, Merck’s Keytruda, Eli Lilly's Gemcitabine works.
4. We've not had any significant "fails" in 20 years.
5. The Phase 1a trial includes a single ascending dose study, a multiple ascending dose study and a food effects study. If the results are as good as we expect - and all the news has been encouraging to date - a big pharma is likely to swoop in with a licencing deal.
6. We already know that the safety and pharmacokinetics data from the initial cohorts in Part 1 of the SDC-1801 trial indicate a favourable profile and fully support oral dosing of patients once daily.
7. We have been briefed that the full safety data from the Phase 1a trial is expected to be available during Q2. We are in this period, so news could come at any time.
In summary, those with a vision and a medium term strategy to "Mega Multi-Bag" are in the right place at exactly the right time at these prices.
And finally, a reminder that TPST went up over 3900% (yes X39) last September in just a few days when it announced favourable data.
I have an average of just under 30p and 50p (SIPP vs ISA). But before the 10p raise they were a LOT higher so I'm quite happy with 40p and a steady rise north.
All these sells are being hoovered up.
Momentum is growing and the exciting thing for me is what will come next. The last RNS indicated "non-dilutive funding" which is probably code for a licence deal but could also mean a JV of some sort. For those here who would like to get news of a TO and think we all would at the right price but the window where a TO could be done is rapidly closing as once a licence deal is done then, we will have our partner who will hopefully push 1801 to market. 1802 will still be on the market and could theoretically be for sale but why would a pharma buy when they could licence? IMO, any pharma looking to make an offer for everything has until a licence deal is inked. Maybe less than 6 weeks? I'm happy with both scenarios but TO rumours may start soon, especially as Tim is BIO 2024 in 3 weeks time, where he is actively trying to book meetings in.
Licence, JV or TO? My gut says licence but if Tim has more than one meeting then we could be in a bidding scenario.
To people like myself who are in at a high level 40p doesn't really excite, but its a step in the right direction I suppose.
Yes and great to see Bobbler predicting 40p next. He's one to listen to, if you are a newbie. A few posters on here like Bobbler, RMM, Brighty etc nailed it during 2020 and 2021 with their predictions of 450p (post consolidation) a share. These & others were posting from sub 1p about the likely timescale of hitting 2p, 4p, 8p, 9p (450p) etc and do you know what? Their predictions were 100% right. Bobbler is someone who has got it spot on in the past and has demonstrated that he understands how this share price fluctuates just prior to news. Excellent to see him posting his predictions again.
Finally! Just bought £15k at 36p
2 shares. That's all you can get.
NT to buy at the moment on HL.
Not even £10 will be accepted.
Seems .35 broken on first attack happy days
And a £20k
From 8.30, when was auction style price but no auction
J & J all day.
Good luck when the RNS drops.
So the death spiral has turned out to have been just a slightly scary log flume and it appears that particular log has now been flushed away.
Shorters can get stuffed.
Yes and you only have to see what happened to a similar bombed out share price with Tempest Therapeutics to see what’s possible. They had dropped to an all-time low (just like Sareum) and then positive data was revealed that saw the share price surge by x 39 in 1 week last September. BIG gains happen in this sector. We know that because SAR has already gone up x 46 before. If the data is positive it will start the firing gun for big pharma to do a licencing deal. At that stage our share price will then rocket. We are on the launch pad!
Added another £2k this morning, caught a dip at £00.324.
Lowered my average to £1.07, still under water but it feels like the tides turned.
GLA to all the LTH
Just the one na quick one too.
Where to next. GLA
35p wonder if this will need two rounds or just the one attack to fall
Morning all, hope we all enjoyed the sunshine over the weekend. Loving the (justified) optimism this morning. We are due a rally after months of frustration with RF - fingers crossed we never see the likes of them again.
On the topic of licence - should we receive anything upwards of £20m up front (highly likely given the field we are in and how good are safety data could be), this will not only be great for 1801.
We will have zero funding worries, zero dilution and be able to turbo charge progress on multiple fronts at the same time. 1802 will be fast tracked into clinic as soon as possible.
The other positive (I'm hoping) is we will surely have learned from CRUK about how (not) to draw up a contract. Milestones with consequences for inaction must be included in the agreement.
Looks like 34 may go
Hi, SOG. Research is pointing to Johnson and Johnson. Their patent for psoriasis treatment, Stelara, targets psoriasis, psoriatic arthritis and Crohn’s disease. Its patent appears be expiring soon. Stelara has annual sales of over $7.5 billion. i.e. great news for Sareum, as SDC1801 is aimed at psoriasis (& other diseases). However, I wouldn't rule out AZ, GSK, Eli Lilly, Merck & Co, Amgen, BMS or Sanofi either for a licencing deal. Takeda, by the way, is also one to watch re licencing SDC1801. The good news is they all have very deep pockets.....
Good luck, Brighty